Zymeworks Inc. announced on April 25, 2025, the presentation of six posters with new preclinical data from its preclinical, development-stage, and clinical programs at the American Association for Cancer Research (AACR) Annual Meeting. The presentations highlighted progress across the company's antibody-drug conjugate (ADC) and T-cell engager (TCE) platforms.
Key findings included data on ZW209, a DLL3-targeting trispecific TCE, which demonstrated potent anti-tumor activity in preclinical small cell lung cancer models by integrating CD28 co-stimulation. An Investigational New Drug (IND) submission for ZW209 is anticipated in the first half of 2026, marking a significant step towards clinical development.
Additionally, Zymeworks presented data on ZW327, a potential first-in-class Ly6E-targeting ADC, showing promising preclinical activity. Updates were also provided for ZW171, a mesothelin-targeting TCE currently in a global Phase 1 clinical study, which exhibited anti-tumor activity in various MSLN-positive tumor models.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.